Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China
Background The association between calcium channel blockers (CCBs) and survival in cancer patients remains unclear and the results of related studies are con icting. The objective of the study was to investigate the association between calcium channel blockers (CCBs) use and survival in cancer patients. Materials and Methods We searched PubMed, EMBASE, Web of Science and Cochrane Library for studies published before January 2016 with the terms related to CCBs and survival in cancer patients. The information was reviewed and extracted by two evaluators independently. Data of publications was extracted and calculated into hazard ratios (HRs) for overall survival (OS). Statistical analysis was performed by using Review Manager 5.3. Results There were 11 studies included in our meta-analysis. Analysis of all studies showed that CCBs use was not associated with survival in cancer patients (HR1.07; 95% CI 0.91-1.25; P0.42). No association between CCBs use and overall survival in cancer patients was existed whether in Asian (HR1.18, 95% CI 0.72-1.93; P0.52) or Caucasian population (HR1.03, 95% CI 0.89-1.20; P0.66). Conclusions There is no evidence that CCBs use is associated with a better or worse outcome of survival in cancer patients.